Is GlaxoSmithKline Pharmaceuticals Limited a good investment? GlaxoSmithKline Pharmaceuticals Limited (GLAXO.NS) is currently trading at 2672.60 INR. Market analysts have a consensus price target of 3053.50 INR. This suggests a potential upside from current levels.
In terms of valuation, the stock trades at a P/E ratio of 40.07. This high multiple suggests investors have priced in significant future growth expectations.
Earnings Schedule: GlaxoSmithKline Pharmaceuticals Limited is expected to release its next earnings report on Feb. 15, 2027. The market consensus estimate for Forward EPS is 79.15.
For income investors, GlaxoSmithKline Pharmaceuticals Limited pays a dividend yield of 2.14%.
Yes, it pays an annual dividend of 57.00 INR (2.14% yield).
GlaxoSmithKline Pharmaceuticals Limited is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.
The next earnings date is projected to be Feb. 15, 2027. The company currently has a trailing EPS of 67.68.
GlaxoSmithKline Pharmaceuticals Limited manufactures, distributes, and trades in pharmaceuticals in India and internationally. The company offers adult and pediatric vaccines, such as Shingrix, Havrix, Fluarix Tetra, Varilrix, Infanrix Hexa, Boostrix, Synflorix, Menveo, and Priorix. It also provides respiratory specialty medicines, such as NUCALA for severe eosinophilic asthma, eosinophilic granulomatosis with polyangiitis, and hypereosinophilic syndrome; Trelegy Ellipta for the treatment of chronic obstructive pulmonary disease; and Seretide. In addition, the company offers general medicines, including Augmentin, an oral antibiotic for respiratory tract infections, surgical prophylaxis, dental infections, and skin infections; Ceftum, an anti-infective medicine; Calpol and Calpol T for pain management; Eltroxin for the treatment of hypothyroidism; Neosporin, Betnovate, T-bact, Physiogel, Tenovate, and Flutivate for dermatology indications; and CobadexCZS and CCM, which are mineral, vitamins, and nutrition products. Further, it provides oncology medicines, including Jemperli and Zejula. The company was formerly known as SmithKline Beecham Pharmaceuticals India Ltd. and changed its name to GlaxoSmithKline Pharmaceuticals Limited in 2001. The company was incorporated in 1924 and is headquartered in Mumbai, India. GlaxoSmithKline Pharmaceuticals Limited operates as a subsidiary of GSK plc.
| Year | Total Dividends |
|---|---|
| ▸2027 |
57.00 INR
|
| July 2, 2027 (estimated) | 57.0000 |
| ▸2026 |
57.00 INR
|
| July 2, 2026 | 57.0000 |
| ▸2025 |
42.00 INR
|
| June 30, 2025 | 42.0000 |
| ▸2024 |
44.00 INR
|
| Nov. 12, 2024 | 12.0000 |
| July 28, 2024 | 32.0000 |
| ▸2023 |
32.00 INR
|
| Aug. 25, 2023 | 32.0000 |
| ▸2022 |
180.00 INR
|
| Aug. 25, 2022 | 60.0000 |
| Aug. 25, 2022 | 30.0000 |
| Aug. 25, 2022 | 90.0000 |
| ▸2021 |
30.00 INR
|
| Aug. 26, 2021 | 30.0000 |
| ▸2020 |
20.00 INR
|
| Aug. 26, 2020 | 20.0000 |
| ▸2019 |
20.00 INR
|
| Aug. 21, 2019 | 20.0000 |
| ▸2018 |
35.00 INR
|
| Aug. 23, 2018 | 35.0000 |
| ▸2017 |
30.00 INR
|
| Aug. 24, 2017 | 30.0000 |
| ▸2016 |
50.00 INR
|
| Aug. 27, 2016 | 50.0000 |
| ▸2015 |
62.50 INR
|
| Aug. 30, 2015 | 62.5000 |
| ▸2014 |
50.00 INR
|
| May 17, 2014 | 50.0000 |
| ▸2013 |
50.00 INR
|
| April 17, 2013 | 50.0000 |
| ▸2012 |
45.00 INR
|
| April 11, 2012 | 45.0000 |
| ▸2011 |
40.00 INR
|
| March 30, 2011 | 40.0000 |
| ▸2010 |
30.00 INR
|
| April 24, 2010 | 30.0000 |
| ▸2009 |
58.00 INR
|
| April 2, 2009 | 58.0000 |
| ▸2008 |
36.00 INR
|
| April 21, 2008 | 36.0000 |
| ▸2007 |
31.00 INR
|
| March 30, 2007 | 31.0000 |
| ▸2006 |
28.00 INR
|
| April 12, 2006 | 28.0000 |
| ▸2005 |
24.00 INR
|
| March 30, 2005 | 24.0000 |
| ▸2004 |
10.00 INR
|
| March 13, 2004 | 10.0000 |
| ▸2003 |
7.00 INR
|
| May 2, 2003 | 7.0000 |
| Name | Payment Date | Status | Amount |
|---|---|---|---|
| GlaxoSmithKline Pharmaceuticals Limited | Jul 02, 2026 | Paid | 57.0 INR |
| Split Date | Split Ratio to 1 |
|---|---|
| Sept. 11, 2018 | 2:1 |
Community Discussion